Valuation: Daxor Corporation

Market Cap 68.31M 60.28M 57.04M 51.72M 96.98M 6.55B 97.93M 684M 264M 3.35B 256M 251M 10.77B P/E 2026 *
-55.7x
P/E 2027 * -390x
Enterprise Value 68.31M 60.28M 57.04M 51.72M 96.98M 6.55B 97.93M 684M 264M 3.35B 256M 251M 10.77B EV / Sales 2026 *
7.34x
EV / Sales 2027 * 4.17x
Free-Float
46.7%
Yield 2026 *
-
Yield 2027 * -
1 day+3.08%
1 week+4.19%
Current month+16.08%
1 month+14.71%
3 months+15.73%
6 months+15.38%
Current year-20.68%
1 week 10.44
Extreme 10.4401
11.86
1 month 9.9
Extreme 9.9
12.25
Current year 8.56
Extreme 8.56
14.75
1 year 8.56
Extreme 8.56
14.76
3 years 6.55
Extreme 6.55
14.76
5 years 6.55
Extreme 6.55
14.76
10 years 3.4
Extreme 3.4001
24.08
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2013
Director of Finance/CFO 69 28/09/2018
Chief Tech/Sci/R&D Officer - 05/06/2024
Director TitleAgeSince
Director/Board Member 91 01/01/1989
Chairman 56 14/02/2017
Director/Board Member 70 22/06/2016
Date Insider Type Main position Quantity % Market Cap. Importance
8/28/26 A Free

Chief Technology Officer

2,451 0.0420%
6/23/26 A Free

Director

2,500 0.0429%
4/8/26 A Buy

Chief Executive Officer

1,000 0.0172%
Change 5-day change 1-year change 3-year change Capi.($)
+3.08%+4.19%-9.72%+24.73% 68.31M
+1.16%-4.49%+7.26%+119.62% 15.24B
+0.20%-9.68%+25.75%+160.95% 12.03B
+0.74%+0.25%-20.48%+23.04% 8.37B
+1.04%-6.22%+14.67%+141.92% 7.35B
+1.08%+0.07%-28.82%-18.69% 6.7B
+0.65%-2.86%-4.82%+14.19% 6.42B
+1.35%+0.66%+9.16%+30.88% 4.75B
+1.13%-2.67%-1.90%+3.26% 3.7B
-0.70%-6.51% - - 3.66B
Average +0.82%-2.68%-0.99%+55.54% 6.83B
Weighted average by Cap. +0.48%-4.41%+2.61%+79.24%

Financials

2026 *2027 *
Net sales 9.3M 8.21M 7.77M 7.04M 13.2M 892M 13.33M 93.16M 35.9M 456M 34.92M 34.16M 1.47B 16.4M 14.47M 13.69M 12.42M 23.28M 1.57B 23.51M 164M 63.31M 804M 61.58M 60.24M 2.59B
Net income -1.2M -1.06M -1M -909K -1.7M -115M -1.72M -12.02M -4.63M -58.8M -4.51M -4.41M -189M -200K -176K -167K -151K -284K -19.19M -287K -2M -772K -9.8M -751K -735K -31.54M
Net Debt - -
Logo Daxor Corporation
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Employees
45
Date Price Change Volume
29/09/26 $11.70 +3.08% 34,261
28/09/26 $11.35 +3.09% 11,713
25/09/26 $11.01 -3.34% 16,421
24/09/26 $11.39 +5.32% 26,830
23/09/26 $10.82 -3.70% 11,373
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.70USD
Average target price
20.00USD
Spread / Average Target
+70.94%

Quarterly revenue - Rate of surprise